Novel Treatments for Chronic Viral Infections

ContraVir seeks to develop and commercialize novel drug treatments to improve the lives of patients suffering from chronic viral infections.

Pipeline Newsroom Investors


Combination Therapies for Hepatitis B

ContraVir is developing potentially curative combination therapies for chronic hepatitis B based on novel antiviral compounds.

TXL™ CRV431 Opportunity

About ContraVir

ContraVir is developing a portfolio of novel compounds against hepatitis B, including TXL, a highly potent prodrug of the antiviral tenofovir (active component of both Vemlidy® and Viread®), now in Phase 2 trials, and CRV431, a next generation cyclophilin inhibitor, in Phase 1 trials.